Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- PhRMA Applauds US Opposition for Annual NHI Price Revision
July 17, 2006
- JPA to Survey GE Drug Use in April-May
July 17, 2006
- Biliary Tract Cancer Added as an Indication of Gemzar
July 17, 2006
- OPINION：Conquering the Stress of Change
July 17, 2006
- Alfresa HD to Focus on Low-cost Operations: Mr Watanabe
July 17, 2006
- Astellas Pharma's R&D to Focus on 3 Promising Products
July 17, 2006
- NHO Slims Its Formulary, Retains Amlodin, Eliminates Norvasc
July 17, 2006
- TeGenero Files for Bankruptcy
July 17, 2006
- Novartis Pharma Taking Steps to Protect Diovan's Sales, Share
July 17, 2006
- Ashitaba Powder Increases Bone Mass in Osteoporotic Rats: Takara Bio
July 17, 2006
- Taiho Licenses TS-1 to sanofi-aventis
July 17, 2006
- New Series：Drug Development Beyond Boundaries -Today's Global Cooperative Clinical Trials- Part I: Overview
July 17, 2006
- Takara Bio Licenses AML Testing Method to InVivo Scribe
July 17, 2006
- Kobayashi to Expand CHC Business
July 17, 2006
- Nihon Schering Ties Up with Daiichi Radioisotope
July 17, 2006
- ADR Offers New Method of Solving Patent Disputes
July 17, 2006
- BUSINESS NEWS IN BRIEF
July 17, 2006
- SEMINAR
July 17, 2006
- 116 Ingredients/402 Products Added in GE Drug Listing
July 17, 2006
- Taiyo Has Most GE Drugs Listed for 11th Year in a Row
July 17, 2006
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…